Lexaria Bioscience (LEXX)
(Delayed Data from NSDQ)
$3.27 USD
+0.14 (4.47%)
Updated Aug 12, 2024 03:59 PM ET
After-Market: $3.22 -0.05 (-1.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Lexaria Bioscience Corp falls in the month of August.
All items in Millions except Per Share data.
8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | 8/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 6 | 12 | 1 | 1 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 0 | 0 | 0 |
Total Current Assets | 2 | 7 | 12 | 2 | 2 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 3 | 8 | 13 | 3 | 3 |
Liabilities & Shareholders Equity | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | 8/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 0 | 0 | 0 | 0 | 0 |
Shareholders Equity | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | 8/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 49 | 47 | 45 | 30 | 26 |
Retained Earnings | -46 | -39 | -32 | -28 | -24 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | 8 | 13 | 2 | 2 |
Total Liabilities & Shareholder's Equity | 3 | 8 | 13 | 3 | 3 |
Total Common Equity | 3 | 8 | 13 | 2 | 2 |
Shares Outstanding | 8.00 | 5.90 | 5.10 | 2.90 | NA |
Book Value Per Share | 0.34 | 1.29 | 2.56 | 0.86 | 0.00 |
Fiscal Year End for Lexaria Bioscience Corp falls in the month of August.
All items in Millions except Per Share data.
5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 5 | 2 | 1 | 3 |
Receivables | 0 | 0 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 1 | 1 |
Total Current Assets | 9 | 5 | 3 | 2 | 4 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 0 | 0 | 1 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 10 | 6 | 4 | 3 | 5 |
Liabilities & Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 0 | 0 | 0 | 0 | 1 |
Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 60 | 54 | 51 | 49 | 49 |
Retained Earnings | -49 | -48 | -47 | -46 | -45 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 10 | 6 | 3 | 3 | 4 |
Total Liabilities & Shareholder's Equity | 10 | 6 | 4 | 3 | 5 |
Total Common Equity | 10 | 6 | 3 | 3 | 4 |
Shares Outstanding | 12.80 | 12.30 | 10.20 | 8.00 | 8.00 |
Book Value Per Share | 0.76 | 0.50 | 0.33 | 0.34 | 0.51 |